Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $155.00 Price Target at Royal Bank Of Canada

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price boosted by equities researchers at Royal Bank Of Canada from $151.00 to $155.00 in a report released on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s target price would suggest a potential upside of 16.23% from the stock’s current price.

Several other equities research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research report on Monday, October 27th. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a “buy” rating and a $152.00 price objective for the company. Truist Financial increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Morgan Stanley set a $183.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, October 24th. Finally, Wells Fargo & Company set a $170.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, October 22nd. Fourteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $179.60.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ traded down $3.86 during trading on Thursday, reaching $133.36. The company’s stock had a trading volume of 273,197 shares, compared to its average volume of 888,340. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The firm has a market capitalization of $8.09 billion, a price-to-earnings ratio of -19.84, a price-to-earnings-growth ratio of 8.49 and a beta of 0.29. Jazz Pharmaceuticals has a 12 month low of $95.49 and a 12 month high of $148.06. The firm has a 50 day moving average price of $132.98 and a 200 day moving average price of $118.98.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.87 by $2.26. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.11 billion. During the same quarter in the previous year, the firm posted $6.54 EPS. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. As a group, equities analysts anticipate that Jazz Pharmaceuticals will post 16.96 EPS for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 3,500 shares of Jazz Pharmaceuticals stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $140.00, for a total value of $490,000.00. Following the transaction, the director directly owned 408,826 shares of the company’s stock, valued at $57,235,640. The trade was a 0.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 11,500 shares of company stock worth $1,525,280 in the last three months. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of JAZZ. Hurley Capital LLC bought a new position in Jazz Pharmaceuticals during the 1st quarter valued at about $25,000. Picton Mahoney Asset Management grew its holdings in Jazz Pharmaceuticals by 2,445.5% during the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock valued at $34,000 after buying an additional 269 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in Jazz Pharmaceuticals by 754.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after buying an additional 234 shares in the last quarter. SVB Wealth LLC purchased a new stake in Jazz Pharmaceuticals during the 1st quarter valued at approximately $36,000. Finally, Hantz Financial Services Inc. grew its holdings in Jazz Pharmaceuticals by 471.4% during the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 297 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.